VolitionRX Limited

All parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the star key followed by the number one on your touchtone phone. If you would like to withdraw your question, please press the star key followed by the number two. If you are using speaker equipment, please lift the handset before making your selections. This conference call is being recorded today, March 26, 2024. I would now like to turn the conference over to Louise Batchelor, Group Chief Marketing and Communications Officer. Please go ahead.

Thank you and welcome everyone to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbour provisions of the Private Securities Litigation Reform Act. of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10K, quarterly reports on Form 10Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward-looking statements made during the course of this call. I am joined today by Mr. Cameron Reynolds, President and Group Chief Executive Officer, Mr. Terry Cuse, Group Chief Financial Officer, Dr. Tom Brutera, Chief Executive Officer of our Volition veterinary subsidiary, and Dr. Andrew Retter, currently Medical Consultant to Volition, but has recently announced due to join Volition in the role of Chief Medical Officer in April 2024. During the call, we will cover Volition's financial and operating results for the fourth quarter and full fiscal year of 2023, along with a discussion of our recent activities and upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. I'll now turn the call over to Cameron Reynolds. Cameron?

Thanks, Lou, and thank you, everyone, for joining Volition's fourth quarter and full year 2023 earnings call today. We appreciate your time, given the busy annual 10K filing season. We will commence the call with a financial report from our group chief financial officer, Terry Hughes, before moving on to a pre-recorded update from Dr. Tom Butera, chief executive officer of VolitionVet, on the rollout of our new QVET cancer test, And I'm delighted to welcome Dr. Andy Retter to the call to provide an update on the UQ nets and capture PCR. As was announced last week, Andy will be joining Volition as our Chief Medical Officer beginning April 1st. Many of you will have heard from Andy previously, but I'd like to formally share his credentials. Dr Retta is an intensive care consultant at Guy's and St Thomas' NHS Foundation Trust in London, where he has worked as a consultant since 2014 and leads clinical governance in critical care. He specialises in the management of severe respiratory failure, ECMO and thrombosis. Dr Retta is the only consultant in the UK to hold dual entry on the specialist register in intensive care and in haematology. and provides national guidance on the management of complex haematology patients in critical care. He will continue his clinical and research duties at Guyston Thomas Foundation Trust after joining Volition. Dr. Retta has worked with Volition in an advisory capacity since January of 2022. To help guide the product development and clinical utility of NICU nets, our CE marked routine blood tests to detect disease associated with mitosis, such as sepsis. The whole team are absolutely delighted to be welcoming Andy more formally into Volition. As Chief Medical Officer, he will be vital to our success, ensuring the needs of the patient are placed at the heart of our research, development and commercialisation activities. It's great to have you on board, Andy, and I must say your enthusiasm for our mission and platform really helps us to fully understand the great importance of the work we do. Following Andy's update, I will wrap up with my thoughts and upcoming milestones and discuss our overall strategy going forward. Without further ado, I'll hand you across to Terry for our financial report.